Objectives: Clinical insomnia is known to affect pain, but mechanisms are unclear. Insomnia can dysregulate inflammatory pathway, and inflammation plays a mediating role in pain. It is unclear whether insomnia-related alterations in inflammation can be modified with insomnia improvement, and if such alterations parallel improvement in pain. The current study objective was to provide proof of concept for the role of insomnia in inflammation and pain by testing whether improving insomnia would reduce pain and related physical function, and, concurrently, modulate inflammatory responses.
S
leep problems, including insomnia, are a significant complaint among adults with chronic pain, with prevalence rates up to 81% reported in older adults with osteoarthritis (OA). 1, 2 Both subjective and objective sleep disturbance can aggravate pain. [3] [4] [5] [6] Conversely, improving sleep quality among adults with co-morbid insomnia and OA can improve OA-related pain, 7 although results are equivocal. 8, 9 Given the role of inflammation in pain, 10, 11 particularly arthritis, 12 improving insomnia may improve pain by modulating inflammatory pathways. Emerging evidence suggests that sleep disturbances, including insomnia, can sensitize or dysregulate inflammatory pathways. 13 Both clinically identified insomnia (that is, via validated selfreport measures) and subjectively poor sleep quality are associated with altered circulating levels of inflammatory cytokines at rest 14, 15 and in response to stress. [16] [17] [18] Clinical evidence to support linkages among poor sleep, inflammatory cytokine levels, and pain comes primarily from crosssectional studies. For example, poorer sleep quality, higher interleukin (IL)-6 levels, and greater pain were associated among otherwise healthy adults with chronic low back pain, but not among those without chronic pain. 19 Recently, laboratory pain-evoked IL-6 responses, but not subjective pain reports, were found to be higher among participants with insomnia disorder than participants without insomnia or knee OA. 17 Lending mechanistic support for a sleep to inflammation to pain pathway, healthy individuals who underwent 4 hours of sleep restriction per night for almost 2 weeks showed higher levels of circulating IL-6 and bodily pain across a subsequent week, compared with those who were assigned to sleep 8 hours during that period. 20 In the current pilot study, we tested whether insomnia improvement led to improved pain, and altered inflammatory cytokine response to pain. To manipulate insomnia, we randomly assigned adults 50 years of age and older, who met diagnostic criteria for insomnia disorder and OA, to either receive cognitive-behavioral therapy for insomnia (CBT-I), or no treatment. We evaluated their morning IL-6 and tumor necrosis factor (TNF)-α levels at rest and in response to pain, and their clinical OA and laboratory pain, before and after insomnia treatment (or no treatment). As our primary aim was to conduct a proof of concept study to experimentally test the role of insomnia improvement in altering inflammation and pain (rather than an efficacy study to determine CBT-I's effects on outcomes), we compared pain-related outcomes and inflammatory responses among those whose insomnia had or had not improved at follow-up. We tested the hypothesis that, relative to individuals without insomnia improvement, those with improved insomnia would evidence OA-pain improvement, less subjective pain, and lower IL-6 levels, in response to laboratory pain testing. TNF-α can increase in circulation in response to acute laboratory stressors, 21 but its release is also observed to be downregulated by IL-6 22 and stress-related adrenergic pathways. 23 Therefore, we tested a nondirectional hypothesis that individuals with insomnia improvement would show altered TNF-α responses to pain testing compared with those without insomnia improvement.
MATERIALS AND METHODS

Participants
Forty-eight participants, 50 to 75 years of age, were recruited through university medical center orthopedics clinics and through advertisements in local newspapers and primary care clinics following university Institutional Review Board approval. Participants were eligible if they had radiographic evidence of knee OA or physician confirmation of diagnosis, reported knee pain and related disability on most days for at least 6 months, met research diagnostic criteria for insomnia disorder, 24 Insomnia Severity Index (ISI) 25 score ≥ 10, and reported either ≥ 2 awakenings per night of > 15 minutes or had wake time after sleep onset > 30 minutes. Participants were excluded for: immune-related and psychiatric-related health conditions (eg, rheumatoid arthritis, heart or blood vessel disease, uncontrolled diabetes, untreated depression, history of bipolar disorder); regular use of systemic corticosteroids; contraindications for nociceptive flexion reflex (NFR) and/or cold pressor test (CPT); prior bilateral hip or knee replacement or prosthetics; body mass index > 39 kg/m 2 ; dementia or cognitive impairment diagnosis or Mini Mental Examination score ≥ 24; active substance dependence (from MINI International Neuropsychiatric Exam 26 ); untreated hypertension; use of antipsychotics, mood stabilizers, sedative hypnotics, opiate analgesics, or unwilling to discontinue their use, with a 2-week washout period before study start; an Apnea Hypopnea Index 27 ≥ 10 (controlled apnea via positive airway pressure treatment was not exclusionary) or Periodic Limb Movement Index 27 with arousals ≥ 15. Women were postmenopausal. Following an overnight laboratory sleep screening (with 1 eligible participant withdrawing before sleep screening), 33 participants remained eligible for the study; 30 completed the study. All participants provided informed consent for participation.
Procedures
Objective sleep screenings and data scoring were conducted via overnight, laboratory-based, polysomnography (PSG) using Embla N7000 (Embla Systems Inc., Broomfield, CO), according to established guidelines. 27 Bedtime was set between 9:30 to 11:00 PM and matched participant's average self-reported bedtime. Eligible participants were invited back the next evening to complete a separate baseline PSG assessment.
The morning after 8-hour baseline PSG recording, participants were escorted to the Clinical Research Center (CRC) at 8:00 AM. To ensure minimal influence of dietary consumption on inflammatory pathways, a CRC bionutritionist designed a standardized breakfast for participants who contained foods choices with low inflammatory impact (eg, oatmeal, whole grain toast, fruit, low cholesterol egg and vegetable omelet). To avoid physiological stress due to caffeine withdrawal, caffeinated coffee or tea was allowed but limited to 6 oz (if selected) and was consumed~2 hours before baseline blood draw (caffeine consumption was unrelated to study outcomes). Following the standardized breakfast, a research nurse attached an indwelling venous cannula to the participants' nondominant arm for unobtrusive blood sampling. Participants completed self-report instruments and sat quietly for a 30-minute adaptation period. Participants then were prepped for pain testing (electrodes attached) and participated in laboratory pain testing, comprising multiple trials of electrical stimulation to the ankle (NFR threshold testing [In some study samples, up to 50% of participants undergoing NFR threshold testing do not show evidence of an NFR, 28 as was the case with our sample; 40% did not show evidence of an NFR. As such, NFR testing data are not reported here.] detailed in France et al 28 ) followed by a CPT. For CPT, we followed procedures previously used to assess IL-6 responses to pain. 29 Specifically, participants immersed their hand, or foot (participants' choice), in a cold water bath maintained at 4°C for 30 seconds for 4 repeated immersions with 2 minutes in between immersions. For a fifth immersion, participants were asked to keep their hand (or foot) in the water for as long as tolerated, but not > 3 minutes. Following pain testing, participants sat quietly for 90 minutes, and completed self-report instruments and had blood sampled.
At the end of the baseline assessment, participants were randomized to either behavioral sleep intervention or no intervention. Participants assigned to sleep intervention participated in a 6-week manualized behavioral sleep therapy, CBT-I, an efficacious intervention for insomnia in patients with comorbid insomnia and chronic pain. 30 Participants assigned to the no intervention condition received 6 weekly "check-in" calls. At weeks 4 and 7 following baseline, all participants were interviewed by phone to provide self-reports on insomnia severity, pain, and potential changes to study-relevant medications (eg, hypnotics, antidepressants). Within 2 weeks following the 6-week intervention period, participants returned for postintervention assessment, at which time all assessments conducted at baseline were repeated.
Assessments
The ISI 25 was assessed at baseline and postintervention. Clinical OA pain was measured by the Western Ontario and McMaster University OA (WOMAC) Index, 31 providing a total scale score as well as subscale scores for pain, stiffness, and physical function. The Knee Pain Scale (KPS 32 ) also indexed clinical OA pain, with 2 subscales measuring pain with transfer activities (eg, getting out of bed) and ambulation or climbing (eg, stairs). Subjective pain was verbally reported after each CPT water immersion (every 15 s) on a scale of 0 (no pain), 50 (pain), and 100 (excruciating pain). The amount of time participants kept their hand (or foot) immersed in the cold water bath provided a measure of pain tolerance.
Serum Cytokine Measurement
Blood samples for analysis were drawn into serum tubes from the indwelling cannula immediately centrifuged and frozen at −80°C. Samples were drawn at the end of the adaptation period (postadaptation), after NFR electrode preparation (immediately before pain testing), and at 5 time points following pain testing (immediately following and at 20, 40, 60, and 90 min). IL-6 and TNF-α were assayed in duplicate (CVs < 0.10) using Quantikine high sensitivity (HS) ELISA kits and standards (R&D Systems, Minneapolis, MN), with mean minimum detectable limits of 0.039 pg/mL (IL-6) and 0.106 pg/mL (TNF).
Statistical Analyses
A manipulation check was conducted with ANOVA testing insomnia severity differences (ISI scores) at followup by CBT-I versus control, controlling for sex and baseline insomnia severity. Insomnia improvement was indexed by ISI severity <8 (yes) or ≥ 8 (no). Although we used a higher ISI cutoff for study eligibility, we used the more conservative validated cutoff of 8 to distinguish between those who had improved to the point of having no insomnia (ISI range of 0 to 7) and those with some remaining level of insomnia (ISI of ≥ 8). In validation work, a cutoff of 8 identified 98.2% of individuals without an insomnia diagnosis in a clinical sample and 98.3% in a community sample. 33 IL-6 levels were skewed (Kolmogorov-Smirnov tests, P < 0.05) and, therefore, log transformed; TNF-α values were not skewed and absolute values were used in analyses. Two participants had outlying cytokine values that were trimmed to within 3 mean SDs.
Effects of insomnia improvement on clinical and cold pressor pain at follow-up were tested with repeated measures analysis of covariance, adjusting for age, sex, and insomnia severity at baseline. To test effects of insomnia improvement on inflammatory cytokine responses to pain testing, mixed effects models with random intercepts were fit to IL-6 and TNF-α at follow-up, and accounted for correlation in measurements from each participants across time. Independent variables assessed in each model were insomnia improvement at follow-up (yes vs. no) and time (immediately, 20-, 40-, 60-, and 90 min after pain testing), as well as their interactions; age, sex, baseline insomnia severity, and baseline level of the dependent variable (IL-6 or TNF-α) were included as covariates. Models for IL-6 included the quadratic term after visual inspection of IL-6 change over the visits. Hand or foot immersion during CPT was considered a potential covariate; however, only 1 participant chose to immerse her foot in the cold water bath rather than her hand. Excluding this participant from analyses did not alter outcomes. Control for medication changes were also planned a priori; however, there were no reported changes to medications across the 10 week study period in this sample.
RESULTS
Sample Characteristics
Demographics and medication use for the total sample, and by insomnia status at follow-up, can be found in Table 1 . The mean age of the sample was 61 (SD = 6.64), and the majority were female (60%). The sample comprised predominantly White, non-Hispanic (87%) participants, followed by African-American (7%) and White, Hispanic (3%) participants.
Baseline Equivalency Tests and Manipulation Check for CBT-I Effects on Insomnia Severity
There were no baseline differences in insomnia severity between the CBT-I group (n = 16; M = 15.19, SD = 2.99) and controls (n = 14; M = 15.65, SD = 3.86; t 31 = 0.38, P = 0.71). Men (M = 16.33, SD = 2.71) reported higher insomnia severity than women (M = 14.17, SD = 2.73; t 1 = 2.14, P = 0.04). At the 8-week follow-up, insomnia severity scores in the CBT-I group (M adj = 6.32, SE = 1.14) were significantly lower than in the control group (M adj = 13.07, SE = 1.23), adjusting for sex and baseline insomnia severity (F 1,29 = 15.09, P = 0.001). The effect size for CBT-I on insomnia severity score (d = 1.04) was comparable with our prior work examining efficacy of CBT-I on insomnia severity in individuals with chronic, noncancer pain. 34 
Operationalizing Clinical Insomnia Severity Improvement for Hypothesis Testing
Of the 16 individuals assigned to the CBT-I group, 6 (37.5%) maintained ISI severity score ≥ 8 at follow-up. Further, 2 of 14 (16.8%) participants assigned to the control group showed ISI severity <8 at follow-up, indicating improved insomnia. Sex distribution was not different across insomnia improvement categories at follow-up (χ 2 = 0.52, P = 0.54). Final groups used for hypothesis testing included participants with (n = 12, female, 67%) vs. without (n = 18; female, 56%) insomnia improvement. Insomnia severity scores did not differ between the insomnia severity improvement (yes/no) groups (P = 0.24).
To ensure baseline equivalence on pain and inflammatory marker outcomes, those with and without insomnia improvement at follow-up were compared on WOMAC, KPS, CPT pain and tolerance, and IL-6 and TNF-α response across the baseline laboratory session. As shown in Table 2 , there was no evidence of baseline differences on the physical function or pain measures. Figures 1A and C show IL-6 and TNF-α trajectories across the baseline pain testing session. Preliminary analysis of the IL-6 data across the session indicated a curvilinear (quadratic) change across time. A mixed model testing change in IL-6 across the baseline session by insomnia improvement, controlling for age, sex, and baseline value, indicated statistically significant change across time (quadratic; F 1,136 = 6.56, P < 0.001), but no significant group effect (insomnia improvement: F 1,45.27 = 0.78, P = 0.38), or interaction of insomnia improvement×time (quadratic) (F 1,136 = 0.70, P = 0.40). At 90 minutes after pain testing at the baseline session, mean IL-6 levels adjusted for age and sex (M adj = 0.42, SE = 0.06) were higher compared with postadaptation period levels across the groups (M adj = 0.11, SE = 0.07; P < 0.001), with no observed group differences (P = 0.70). Findings for TNF at the baseline sessions were similar, with no group effect of insomnia improvement (F 1,24.97 = 1.40, P = 0.25), and no group differences across time (baseline session: time (F 1,26 = 25.66, P < 0.001), insomnia improvement×time (F 1,26 = 0.16, P = 0.69), after controlling for age and sex. In contrast to IL-6, however, participants had significantly lower TNF levels at 90 minutes after pain testing compared with baseline, after C D A B FIGURE 1. Log transformed IL-6 and TNF at baseline (A, C) and follow-up (B, D) by insomnia improvement (improver vs. nonimprover) at follow-up. Values are marginal means (with SE bars) from models adjusted for age, sex, and baseline cytokine value. Adjusted mean differences between insomnia improvers versus nonimprovers significant at *P < 0.05; †P < 0.10). IL-6 indicates interleukin-6; TNF, tumor necrosis factor. Baseline insomnia severity was greater, though not significantly, among participants who did not evidence improved insomnia at follow-up (M = 15.61, SD = 3.01), relative to those with insomnia improvement (M = 14.17, SD = 2.55; t 1 = −1.36, P = 0.18). As such, baseline insomnia severity was included as a covariate in hypothesis testing. Table 2 displays adjusted mean scores from the WOMAC and KPS, and subjective pain ratings from CPT at baseline and follow-up by insomnia improvement at followup. For clinical pain measures, participants with insomnia improvement showed a larger decline in WOMAC total scores compared with those without insomnia improvement after controlling for baseline insomnia severity, sex, age, and baseline WOMAC total score (insomnia improvement×visit: F 1,24 = 5.64, P = 0.03). Notably, the difference in average WOMAC scores between the groups at follow-up was 18.25 points, suggesting a clinically important difference in overall functioning. 35 In addition, WOMAC scores declined on average for the insomnia improvement group by 9.06 points, further suggesting a clinically important change in participants with insomnia improvement. 36 When examining WOMAC subscales, significantly greater change was evident on the physical function subscale for those with insomnia improvement compared with those without (insomnia improvement×visit: F 1,24 = 4.76, P = 0.04). No significant differences were observed on the pain subscale (insomnia improvement×visit: F 1,25 = 2.85, P = 0.10) or the stiffness subscale (insomnia improvement×visit: F 1,25 = 2.35, P = 0.14).
Insomnia Improvement Effects on Clinical Pain and Acute Pain
With respect to the KPS, reported pain intensity on the transfer activities subscale (ie, getting in/out of a bed, chair, or car) showed a significantly greater decline at follow-up among participants with insomnia improvement as compared with those without insomnia improvement (insomnia improvement×visit: F 1,25 = 9.25, P = 0.01). In contrast, there was no difference between the groups over time on the ambulation/climbing intensity subscale, suggesting similar pain intensity while walking and climbing up or down stairs (insomnia improvement×visit: F 1,25 = 2.17, P = 0.15).
When examining acute pain ratings during the CPT, there were no significant differences between those with and without insomnia improvement for mean change in pain ratings from baseline to follow-up (insomnia improvement×visit: F 1,28 = 1.52, P = 0.23), or for pain tolerance (insomnia improvement×visit: F 1,24 = 1.15, P = 0.30), controlling for sex, age, and baseline insomnia severity. Further, at follow-up there was no significant difference between the groups for mean pain ratings across the 4 trials at 15 seconds (F 1,24 = 0.28, P = 0.60) or 30 seconds (F 1,24 = 1.16, P = 0.29) into the CPT, when controlling for sex, age, and baseline insomnia severity.
Insomnia Improvement Effects on Inflammatory Cytokine Responses
When assessing IL-6 response at the follow-up session, The insomnia improvement×time (quadratic) interaction was significant (F 1,138 = 11.47, P = 0.001); participants who had insomnia improvement at follow-up showed significantly lower IL-6 levels immediately before and following pain testing (P-values <0.05), reaching similar levels of nonimprovers by 60 minutes after pain testing (Fig. 1B) . On the basis of the group term, insomnia improvers' overall IL-6 levels were lower than nonimprovers after adjustment for baseline, although this difference was not significant (insomnia improvement: F 1,127.64 = 3.81, P = 0.053).
For the full model testing TNF, there was a main effect of time (F 1,27 = 15.80, P < 0.001), but the insomnia improvement×time interaction was not significant (F 1,27 = 1.87, P = 0.18), or was there a significant group effect (F 1,25.21 = 0.11, P = 0.74). Visual data examination (Fig. 1D) , however, suggested a potential difference between the groups. In a post hoc, exploratory analysis stratified by group, after controlling for age and sex, participants with insomnia improvement no longer showed significant change in TNF-α across the session as they did at baseline (baseline session: time (F 1,10 = 13.97, P = 0.004); follow-up session (F 1,10 = 3.44, P = 0.09), whereas those with insomnia at follow-up showed the same significant decline observed at baseline session (baseline session: time (F 1,16 = 15.98, P = 0.001); follow-up session (F 1,17 = 16.80, P = 0.001), with significantly lower TNF at 90 minutes after pain testing compared with their postadaptation period level, adjusted for age and sex (postadaptation: M adj = 0.93, SE = 0.08, 90 min after pain testing: M adj = 0.79, SE = 0.07; P < 0.03).
Exploratory Analysis of Correlations Among IL-6, Pain, and Insomnia Severity Changes
Our pilot study was designed a priori to examine whether insomnia improvement affected both pain and inflammatory cytokines outcomes, providing proof of concept for a path model (and a larger powered clinical trial) whereby insomnia improvement leads to changes in inflammation and, in turn, improvements in pain. To provide further proof of concept for links between inflammatory cytokine changes and pain improvement in older adults with knee OA, we explored whether changes from baseline to follow-up visit in mean IL-6 levels (averaging values from before to 40 min after pain testing and creating change scores [mean IL-6 level at follow-up minus mean IL-6 level at baseline]) correlated with changes in WOMAC scores and KPS transfer intensity scores, across the sample. From partial correlation analysis controlling for age and sex, larger declines in mean IL-6 levels from baseline to followup were associated with larger decreases in WOMAC total scores (ie, WOMAC score at follow-up minus score at baseline), representing greater improvements in clinical pain over time (r p = 0.40, P = 0.04); IL-6 change over time was not associated with KPS transfer intensity scores.
Finally, we determined if the degree of change in insomnia severity from baseline to follow-up was associated with changes in IL-6 levels and clinical pain across the sample. After controlling for age and sex, larger declines in ISI scores were associated with larger declines in KPS transfer intensity scores (r p = 0.45, P = 0.02); insomnia severity change showed a small but nonsignificant correlation with change in WOMAC scores (r p = 0.22, P = 0.28). ISI scores were not associated with IL-6 mean level change (r p = −0.03, P = 0.89).
DISCUSSION
In this pilot study of older adults with comorbid insomnia and knee OA, improvement in insomnia symptoms was related to altered inflammatory cytokine responses to pain testing, enhancement of physical function, and reduction in knee pain during transfer activities. Notably, insomnia improvers showed clinically meaningful improvements in their physical function. Altogether, these findings suggest that insomnia improvement holds promise as a means to modulate inflammatory pathways in adults with chronic pain. Given evidence that inflammation can contribute to pain sensitivity, and that chronic pain may increase mortality risk from inflammatory-related disease, 37 further elaboration of inflammatory mechanisms linking insomnia to clinical pain could support translation to more targeted interventions for pain.
In a prior cross-sectional study, 17 insomnia was associated with larger IL-6 responses to pain testing in older adults with or without knee OA or insomnia. We hypothesized that insomnia improvement would be associated with lower IL-6 response to laboratory pain testing, which was partially supported. Relative to older adults without insomnia improvement, those with insomnia improvement showed an attenuation in the earlier rise in circulating IL-6 levels that was observed in the baseline laboratory pain testing session. Further, at the follow-up visit, insomnia improvers showed significantly lower IL-6 levels before the start of pain testing compared with nonimprovers. At 60 minutes post-CPT, insomnia improvers' IL-6 levels had increased to a level comparable with nonimprovers. IL-6 increases are typically evident at 40 to 90 minutes poststressor or pain provocation. 21, 38 This pattern of results may reflect potential effects of insomnia improvement on adaptation to the pain testing situation, via multiple pathways, including better emotion and physiological regulation. Subjectively poor sleep is associated with greater negative affect and IL-6 responses to acute stressors in older adults, 16 and insomnia is associated with dysregulation of physiological stress systems. 39, 40 Thus, the delayed rise in IL-6 across the pain testing session among insomnia improvers may reflect better emotion regulation in anticipation of noxious stimulation. Given the integral overlap among somatosensory and physiological stress systems, further study is needed to elaborate the neurobiological and likely bidirectional pathways through which inflammation may link chronic pain and poor sleep.
Although our findings of increased circulating IL-6 in response to laboratory pain testing are in line with previous studies, 17, 29 less is known about pain-evoked TNF-α response, although TNF-α is responsive to acute stressors. 21 In the current study, TNF-α showed an overall decline in response to the laboratory pain testing at the baseline testing session. Overall, TNF-α was modestly affected by insomnia improvement, with findings from the exploratory analysis suggesting that insomnia improvement was associated with more stable levels of TNF-α in response to laboratory pain testing. Existing research on the interplay between IL-6 and TNF-α may be relevant to this preliminary observation. Although we did not observe any consistent associations between IL-6 and TNF-α in our small pilot study (data not shown), it is known that IL-6 has inhibitory effects on TNF-α, 22 presumably via sympathetic nervous system modulation. 23 As insomnia is characterized by increased sympathetic activation, 41, 42 if insomnia improvement attenuates sympathetic arousal and associated pathways, TNF production could be affected. Investigations among the interplay among sympathetic activation and inflammation in insomnia, and implications for pain, may shed light on these integrative pathways.
The current study expands on previous research by examining sleep and pain-associated inflammation and inflammatory responses longitudinally, rather than just cross-sectionally. 16, 17, 19, 29 Further, our design afforded comparison of adults with chronic knee pain who demonstrated improvements in insomnia versus those who did not. This prospective design provides novel proof of concept for the role of insomnia improvement in altering inflammatory responses stimulated by an acute stressor. Chronic pain itself is associated with dysregulated stress responses, including inflammatory responses. 43 Specific mechanisms of insomniamediated inflammatory alterations, and their causal role in pain improvement, remain to be identified by future trials.
As noted previously, while some prior trials of CBT-I have observed significant or clinically meaningful effects of CBT-I, 7 or insomnia and sleep improvement, 8, 44 on clinical pain outcomes in older adults with insomnia, some have not. 9 Although not a primary aim of the study, for comparison with these existing larger scale clinical trials, we note that the CBT-I intervention here showed statistically significant effects on self-reported OA pain from the WOMAC (Cohen's d = 0.45; data not shown). Moreover, for comparison with other trials, our sample had a mean WOMAC pain subscale score of 10.6 at baseline, which is comparable or even higher than baseline scores in knee OA trials. 45 Nevertheless, our sample was highly selective given the stringent inclusion criteria, reducing heterogeneity due to factors such as depression, obesity, and inflammatory conditions. This selection was intended to improve signal to noise ratio to observe treatment effects. As a result, our findings may have reduced generalizability, given that these factors are among common comorbidities of chronic pain.
The observation that insomnia improvement had differential effects on clinical versus experimental pain suggests that sleep benefits may differ as a function of nociceptive fiber involvement. Cytokines contribute to persistent arthritic pain primarily via sensitization of nociceptive C-fibers, and to a lesser extent via sensitization of nociceptive A-delta fibers. 46 In contrast, the experimental pain induced by the CPT is mediated primarily by A-delta fibers. 47 Hence, insomnia improvement may help to reduce the dull, aching sensations that are characteristic of C-fiber activation and OA pain, but have little or no effect on A-delta mediated sharp, cold pressor pain sensations.
The small sample size of this pilot study is an obvious limitation, as larger studies that take comorbidities into explicit consideration are needed. Although we found an association between the magnitude of insomnia improvement and improvement in transfer-related knee pain, larger trials are needed to discern the degree to which insomnia severity must improve to observe clinically meaningful changes in pain and inflammation. Given our small sample, we were also unable to examine how medication and supplement use, such as use of COX-II inhibitors or herbal supplements, may moderate or mediate insomnia improvement effects on outcomes. In addition, although we did not observe changes in important study-relevant medications across the study period for any participant, medication use was self-reported, which is a limitation. Despite these limitations, the current findings suggest that improving insomnia among older adults with chronic knee OA pain can alter acute inflammatory responses to pain stimulation and diminish clinical pain. These preliminary findings underscore inflammatory pathways as a possible mechanism linking insomnia treatment to reduced clinical pain. These findings also suggest further study of CBT-I and its potential efficacy for altering neurobiological pathways in pain.
